AstraZeneca says its China operations president under investigation
Adds detail on share decline, paragraph 1, on separate investigation of other employees that began in September, paragraph 7, and context in final two paragraphs
By Maggie Fick
Oct 30 (Reuters) -AstraZeneca's AZN.L China president is under investigation and is cooperating with Chinese authorities, the company said on Wednesday, sending its shares down as much as 5.3% and making it the biggest loser on London's FTSE 100.
It was not immediately clear whether the executive Leon Wang was in the custody of the Chinese government. When asked about Wang's whereabouts, a company spokesperson only reiterated that the executive was under investigation.
The Anglo-Swedish company has for years had one of the strongest market positions among western drugmakers in China, the world's No.2 pharmaceuticals market behind the United States. It has invested heavily in the country, announcing plans last year to build a $450 million factory and more recently signing a number of licensing deals with Chinese companies.
In a statement, the drugmaker said its Chinese operations were "under the leadership of the current general manager of AstraZeneca China," without providing further details.
"If requested, AstraZeneca will fully cooperate with the investigation", the statement read.
AstraZeneca shares were down 5.2% at 1429 GMT.
In September, China detained five of AstraZeneca's current and former employees for questioning. At the time, Bloomberg News reported that the employees were detained for questioning about potential illegal activities.
The company has not given details about the detention in September and a spokesperson had no comment on Wednesday on the status of the employees being held.
Other foreign drugmakers have been subject to anti-graft investigation in China.
Last year, multinational pharma companies including South African drugmaker Aspen APNJ.J suffered business disruptions and lost orders from hospitals in China after Beijing intensified an anti-corruption drive in the nation's healthcare sector.
Reporting by Maggie Fick in London;
Additional reporting by Yadarisa Shabong in Bengaluru and Ludwig Burger in Frankfurt;
Editing by Krishna Chandra Eluri, Tomasz Janowski and Barbara Lewis
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
